Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Prefer textile, pharma, IT space: Deepak Shenoy

      Deepak Shenoy, Founder of capitalmind.in is of the view that one may prefer textile, pharma and IT space.

    • Buy SBI Canara Bank, Glenmark, Jubilant Food: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma, Jubilant Foodworks and Jubilant Foodworks.

    • Go long in Glenmark, Aurobindo Pharma: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Group recommends going long in Glenmark Pharma and Aurobindo Pharma.

    • Ajay Bodke positive on Glenmark Pharma; target Rs 1186

      Ajay Bodke of Prabhudas Lilladher is positive on Glenmark Pharma and expects target price at around Rs 1186 over a one year period.

    • Here are top 10 stocks to focus on April 20

      Here are top 10 stocks to focus on April 20 – Lupin, Bharat Forge, Reliance Industries, LIC Housing Finance, Delta Corp, Titagarh Wagons, Clariant Chemicals, Glenmark Pharma, Bhushan Steel and NMDC.

    • See 10-15% upside in midcap pharma space: Vineet Bhatnagar

      Vineet Bhatnagar - MD at Phillip Capital expects 10-15 percent upside in midcap pharma stocks including Glenmark Pharma, Divis Laboratories, Torrent Pharma and Cadila Healthcare.

    • Glenmark can outperform, target Rs 1180-1200: TS Harihar

      TS Harihar of HRBV Client Solutions is of the view that Glenmark Pharma can outperform and has a target price of Rs 1180-1200 in the next one quarter.

    • Prefer Glenmark Pharma: Tushar Mahajan

      According to Tushar Mahajan - head of listed futures & options for India at Nomura Financial Advisory, one may prefer Glenmark Pharma.

    • Buy Glenmark, Colgate Palmolive: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Colgate Palmolive and Glenmark Pharma.

    • Here are top 10 stocks to focus on April 15

      Here are top 10 stocks to focus on April 15 - Glenmark Pharma, UPL, ACC, UltraTech Cement, Development Credit Bank, Ashoka Buildcon, Bajaj Auto, Mangalore Chemicals, Deepak Fertilisers and Zuari Agro.

    • Alzheimer drug nod won't impact Lupin, Glenmark: Expert

      Surajit Pal, analyst, Prabhudas Lilladher continues to have a positive outlook on Glenmark with a target price of Rs 1186 per share.

    • Buy Glenmark Pharma, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma.

    • Buy Glenmark Pharma, Bharat Forge, HPCL: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma, Bharat Forge and HPCL.

    • Buy Glenmark Pharma, says Deepak Shenoy

      Deepak Shenoy, founder of capitalmind.in recommends buying Glenmark Pharma.

    • Top buzzing midcap stocks to trade on April 8

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have BPCL, Sesa Sterlite, Glenmark Pharma, GM Breweries, TGB Banquets, Coal India, KRBL, Shree Renuka, CCL Products & Bajaj Hind.

    • Buy Glenmark Pharma, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Glenmark Pharma with a view of few weeks.

    • Buy Idea Cellular, Divis Labs, Glenmark: Manish Hathiramani

      Manish Hathiramani of Deen Dayal Investments recommends buying Idea Cellular, Divis Laboratories and Glenmark Pharma.

    • Look at Prism Cement: Dilip Bhat

      Dilip Bhat of Prabhudas Lilladher is of the view that one may look at Prism Cement and KPIT Tech.

    • Buy Glenmark Pharma 860 Call; sell 880 Call: VK Sharma

      VK Sharma of HDFC Securities recommends buying Glenmark Pharma 860 call and sell 880 Call.

    • Buy Glenmark Pharma 860 Call: Gaurav Bissa

      Gaurav Bissa of LKP Securities recommends buying Glenmark Pharma 860 Call.

    • Go long in Glenmark Pharma, says Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Group recommends going long in Glenmark Pharma at current level with a target of Rs 920-930.

    • Glenmark Pharma may test Rs 900-920: Amit Gupta

      Amit Gupta of ICICIdirect is of the view that Glenmark Pharma may test Rs 900-920 in the short term.

    • Prefer Glenmark Pharma, Suven Lifesciences: Prakash Diwan

      Prakash Diwan of Altamount Capital Management is of the view that one may prefer Glenmark Pharma and Suven Lifesciences.

    • Buy HUL, Dabur, Cipla, Glenmark: CK Narayan

      According to CK Narayan, MD at Growth Avenues, one can buy Hindustan Unilever, Dabur India, Cipla and Glenmark Pharma.

    • Buy Glenmark Pharma, says Gaurav Bissa

      Gaurav Bissa, Derivatives Analyst at LKP Securities recommends buying Glenmark Pharma as the stock may head above Rs 895.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347